Literature DB >> 8173486

Retention in methadone maintenance and heroin addicts' risk of death.

J R Caplehorn1, M S Dalton, M C Cluff, A M Petrenas.   

Abstract

A long-term follow-up was made of a cohort of 307 heroin addicts admitted into a high-dose, Australian methadone maintenance programme in the early 1970s. Using data from clinic records, official death records and methadone treatment histories, it was found that subjects were nearly three times as likely to die outside of methadone maintenance as in it (95% CI RR 1.45 to 5.61). Data were further analyzed using Cox regression to investigate the association of maximum daily methadone dose and a change in clinic policy with retention in maintenance treatment. It is estimated that subjects given a maximum daily dose of 80 mg were nearly twice as likely to be discharged during the first three years of maintenance as those given 120 mg (95% CI RR 1.3 to 2.2). The estimated median time in maintenance for subjects given a maximum dose of 120 mg was 1150 days while for 80 mg it was 660 days. It is further estimated that the change in clinic policy from abstinence to indefinite maintenance reduced to one-third subjects' risk of leaving after three years' of treatment (95% CI RR 0.19 to 0.54). It is concluded that, in order to minimize heroin addicts' risk of death, they should be offered indefinite, high-dose methadone maintenance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8173486     DOI: 10.1111/j.1360-0443.1994.tb00879.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  37 in total

1.  Beliefs about methadone in an inner-city methadone clinic.

Authors:  Sharon Stancliff; Julie Elana Myers; Stuart Steiner; Ernest Drucker
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

2.  Why we object to NAOMI. Heroin maintenance in Canada.

Authors:  Meldon Kahan; Anita Srivastava; Kay Shen
Journal:  Can Fam Physician       Date:  2006-06       Impact factor: 3.275

Review 3.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

4.  Fatal methadone and heroin overdoses: time trends in England and Wales.

Authors:  J Neeleman; M Farrell
Journal:  J Epidemiol Community Health       Date:  1997-08       Impact factor: 3.710

5.  Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study.

Authors:  Bohdan Nosyk; Huiying Sun; Elizabeth Evans; David C Marsh; M Douglas Anglin; Yih-Ing Hser; Aslam H Anis
Journal:  Addiction       Date:  2012-05-08       Impact factor: 6.526

6.  Emergence of methadone as a street drug in St. Petersburg, Russia.

Authors:  Robert Heimer; Aleksandra Lyubimova; Russell Barbour; Olga S Levina
Journal:  Int J Drug Policy       Date:  2015-10-19

7.  Gender differences in health related quality of life of young heroin users.

Authors:  Antònia Domingo-Salvany; M Teresa Brugal; Gregorio Barrio; Francisco González-Saiz; M José Bravo; Luís de la Fuente
Journal:  Health Qual Life Outcomes       Date:  2010-12-01       Impact factor: 3.186

8.  Leaving buprenorphine treatment: patients' reasons for cessation of care.

Authors:  Jan Gryczynski; Shannon Gwin Mitchell; Jerome H Jaffe; Kevin E O'Grady; Yngvild K Olsen; Robert P Schwartz
Journal:  J Subst Abuse Treat       Date:  2013-10-14

9.  Factors associated with mortality of HIV-positive clients receiving methadone maintenance treatment in China.

Authors:  Enwu Liu; Keming Rou; Jennifer M McGoogan; Lin Pang; Xiaobin Cao; Changhe Wang; Wei Luo; Sheena G Sullivan; Julio S G Montaner; Marc Bulterys; Roger Detels; Zunyou Wu
Journal:  J Infect Dis       Date:  2013-04-16       Impact factor: 5.226

10.  Does methadone maintenance treatment based on the new national guidelines work in a primary care setting?

Authors:  Jenny Keen; Phillip Oliver; Georgina Rowse; Nigel Mathers
Journal:  Br J Gen Pract       Date:  2003-06       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.